Browse News
Filter News
Found 13 articles
-
Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix
1/7/2024
Curevo Vaccine announced positive data from an 876-patient Phase 2 trial of amezosvatein head-to-head versus Shingrix in participants aged 50 years and older.
-
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
12/21/2023
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
4/11/2023
Curevo Vaccine, a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, announced Dr. Guy De La Rosa has joined the company as its new Chief Medical Officer.
-
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
11/16/2022
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
-
Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles
9/15/2022
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced completion of enrollment in a Phase 2b trial of their CRV-101 subunit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.
-
Money on the Move: February 9 – 15
2/16/2022
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in. -
Curevo, a clinical-stage biotechnology company, is developing safe and highly-effective vaccines to fight infectious diseases such as shingles.
-
Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines
2/10/2022
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round.
-
Curevo Vaccine Announces the Approval to Conduct a Phase 1b Clinical Trial in South Africa to Evaluate Safety and Immunogenicity of Its Adjuvanted Subunit Investigational Vaccine, CRV-101, Against Varicella (Chickenpox) in HIV-Positive Children
3/30/2021
Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was granted to move forward with a Phase 1b pediatric clinical trial in South Africa to evaluate the safety, efficacy, and immunogenicity of its non-live investigational vaccine, CRV-101,
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101
9/15/2020
Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious disease of global importance, today announced antibody response data from its completed Phase 1 study investigating the safety, tolerability, and immune system response of CRV-101 in several formulations.
-
Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101
9/26/2019
Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety and tolerability results of their Shingles vaccine candidate, CRV-101.
-
Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate
11/5/2018
Curevo announced today that the U.S. Food and Drug Administration (FDA) has advanced the company's Investigational New Drug (IND) application for CRV-101.